
Zai Lab Ltd
Zai Lab Ltd (ZLAB)
WebsitePrice
Market cap
Next catalystInitiate first-line randomized Phase 3 in Q4 2026, by year-end, based on emerging dataZocilurtatug pelitecan + PD-L1 inhibition — planned first-line ES-SCLC Phase 3 · Trial initiationCompany release ↗
Cash
Chart & Events
Core Clinical
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Zocilurtatug pelitecanZocilurtatug pelitecan + PD-L1 inhibition — planned first-line ES-SCLC Phase 3
DLL3
PreINDP1P2FilingApproved
PreINDP1P2FilingApproved
Approved
PreINDP1P2P3FilingApproved
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Representative pipeline applications
Clinical
Upcoming clinical milestones
Zocilurtatug pelitecanZocilurtatug pelitecan + PD-L1 inhibition — planned first-line ES-SCLC Phase 3
DLL3
PreINDP1P2FilingApproved
Other pipelines
Approved / commercial
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved